Development of a novel cell line‐derived xenograft model of primary herpesvirus 8‐unrelated effusion large B‐cell lymphoma and antitumor activity of birabresib in vitro and in vivo-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Development of a novel cell line‐derived xenograft model of primary herpesvirus 8‐unrelated effusion large B‐cell lymphoma and antitumor activity of birabresib in vitro and in vivo

Published:2021-11-24 Issue:24 Volume:10 Page:8976-8987
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Nishimori Tomohiro¹,Higuchi Tomonori¹^ORCID,Hashida Yumiko¹,Ujihara Takako¹²,Taniguchi Ayuko¹³,Ogasawara Fumiya¹³,Kitamura Naoya⁴,Murakami Ichiro⁵,Kojima Kensuke³,Daibata Masanori¹^ORCID

Affiliation:

1. Department of Microbiology and Infection Kochi Medical School Kochi University Nankoku Japan

2. Science Research Center Kochi University Nankoku Japan

3. Department of Hematology Kochi Medical School Kochi University Nankoku Japan

4. Department of Oral and Maxillofacial Surgery Kochi Medical School Kochi University Nankoku Japan

5. Department of Pathology Kochi Medical School Kochi University Nankoku Japan

Funder

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4394

Reference46 articles.

1. Kaposi's Sarcoma-Associated Herpesvirus/Human Herpesvirus Type 8-Positive Solid Lymphomas

2. Primary Effusion Lymphoma: A Clinicopathological Study of 70 Cases

3. Primary effusion lymphoma: current perspectives

4. Kaposi sarcoma–associated herpesvirus/human herpesvirus 8–associated lymphoproliferative disorders

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas;PLOS Pathogens;2023-01-13

2. Targeting VEGF with bevacizumab inhibits malignant effusion formation of primary human herpesvirus 8‐unrelated effusion large B‐cell lymphoma in vivo;Journal of Cellular and Molecular Medicine;2022-10-09

3. Rituximab;Reactions Weekly;2022-08-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3